Drug Discovery World

JANUARY 9, 2023

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. . Using gene engineering, we are repurposing cancer cells to develop a therapeutic that kills tumour cells and stimulates the immune system to both destroy primary tumors and prevent cancer.” .

Scientist 52

Scientist Gene Editing Gene Engineer 52

Drug Discovery World

NOVEMBER 9, 2023

Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics, on: ‘Anti-GARP/TGFb1 antibodies in new twist – multifunctional shapers of anti-tumour immunity’. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 13, 2023

De Luca will present on Tripkin, a best-in-class potential for tumour-targeted interleukin-2 (IL2) potentiated by tumour necrosis facor (TNF). Stefan Warmuth, PhD, Vice President, Head CMC, Numab Therapeutics, on: ‘Update on Numab’s affinity-balanced PD-L1x4-1BBxHSA trispecific tumour-targeted immunotherapy’.

Protein 59

Protein Antibody Engineer Scientist 59